IL1B and metabolic dysfunction-associated steatotic liver disease: Interestingly, the serum IL-1β (SMD: −2.3; 95% CI: −3.5 to −1.1 pg mL-1; p-value < 0.01) and hepatic caspase-3 (SMD: −2.6; 95% CI: −3.4 to −1.7 AU; p-value < 0.01) levels were notably reduced in NAFLD-induced animals by NAC treatment (Figures 6A,B).